Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · Real-Time Price · USD
37.01
-1.33 (-3.47%)
At close: Aug 25, 2025, 4:00 PM
37.01
0.00 (0.00%)
After-hours: Aug 25, 2025, 4:04 PM EDT
-3.47%
Market Cap4.43B
Revenue (ttm)85.74M
Net Income (ttm)-606.31M
Shares Out 119.66M
EPS (ttm)-5.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,264,599
Open38.37
Previous Close38.34
Day's Range37.00 - 39.12
52-Week Range29.31 - 59.39
Beta0.65
AnalystsBuy
Price Target71.58 (+93.41%)
Earnings DateAug 7, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2004
Employees 498
Stock Exchange NASDAQ
Ticker Symbol CYTK
Full Company Profile

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial Statements

Analyst Summary

According to 13 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $71.58, which is an increase of 93.41% from the latest price.

Price Target
$71.58
(93.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Afic...

8 hours ago - GlobeNewsWire

Cytokinetics: Specialty Franchise With Aficamten And Ulacamten

CYTK's Aficamten is easily their main value driver. It has an oHCM PDUFA for December 26, 2025. Aficamten's late-cycle FDA meeting is in September. Plus, it has a potential future as a monotherapy, pe...

5 days ago - Seeking Alpha

Cytokinetics Names Jim Daly to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19,...

5 days ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 10...

6 days ago - GlobeNewsWire

Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial O...

16 days ago - Seeking Alpha

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China;  Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date

18 days ago - GlobeNewsWire

Cytokinetics Merits A Speculative Buy Rating

Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug ca...

4 weeks ago - Seeking Alpha

Cytokinetics to Announce Second Quarter Results On August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00...

4 weeks ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,...

5 weeks ago - GlobeNewsWire

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy

6 weeks ago - GlobeNewsWire

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations  Aligned with Corporate Values Deadline for Applications is August 4 th , 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- C...

2 months ago - GlobeNewsWire

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a ...

3 months ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions

3 months ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C...

3 months ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted REMS. Positive phase 3 MAPLE-HCM study results show aficamten significantly ou...

3 months ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire

Cytokinetics' heart disease drug meets main goal in late-stage study

Cytokinetics said on Tuesday its experimental heart disease drug met the main goal in a late-stage study.

3 months ago - Reuters

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., M...

3 months ago - GlobeNewsWire

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...

3 months ago - Accesswire